{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003055","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.573560+00:00","generated_at":"2026-06-28T12:49:15.613194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q3 cash $803.6M; FT596/FT516 show 71% and 73% ORR in lymphoma Ph1","bullets":["Cash, equivalents and investments $803.6M at Sept 30, 2021; revenue $14.2M from collaborations.","FT596 in r/r BCL: 71% ORR, 50% CR in single-dose cohorts; no ICANS or GVHD, two low-grade CRS events.","FT516 in r/r BCL: 73% ORR, 55% CR in multi-dose cohorts; 63% responders ongoing at median 5.2 months.","FT819 (iPSC-derived CAR T) first patients dosed; FT576 Ph1 enrollment initiated for multiple myeloma.","R&D expenses $53.1M, G&A $15.7M; shares outstanding 95.4M common, 2.8M preferred (convertible 5:1)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003055","json":"https://secwatch.observer/filing/0000950170-21-003055.json","markdown":"https://secwatch.observer/filing/0000950170-21-003055.md","text":"https://secwatch.observer/filing/0000950170-21-003055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017021003055/0000950170-21-003055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017021003055/fate-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:49:15.613194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}